2315-02-8 Usage
Chemical Properties
Off-White Solid
Uses
Different sources of media describe the Uses of 2315-02-8 differently. You can refer to the following data:
1. muscle relaxant (smooth), cerebral vasodilator
2. Vasoconstrictor, used as a nasal decongestant. An ingredient of Drixin.
3. Oxymetazoline hydrochloride is an α1-AR and α2-AR adrenergic receptor agonist and used as Vasoconstrictor, a nasal decongestant.
Definition
ChEBI: A hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal con
estion.
Therapeutic Function
Nasal decongestant
Biological Activity
Partial α 2A adrenoceptor agonist and α 1A agonist. Agonist/antagonist activity at 5-HT receptors.
Check Digit Verification of cas no
The CAS Registry Mumber 2315-02-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,3,1 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2315-02:
(6*2)+(5*3)+(4*1)+(3*5)+(2*0)+(1*2)=48
48 % 10 = 8
So 2315-02-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)/p+1
2315-02-8Relevant articles and documents
Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
-
Page/Page column 43; 44, (2010/11/28)
The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R1, R2, A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.